Edition:
United Kingdom

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.42USD
8 Dec 2017
Change (% chg)

$-0.01 (-1.87%)
Prev Close
$0.43
Open
$0.42
Day's High
$0.44
Day's Low
$0.40
Volume
43,170
Avg. Vol
184,583
52-wk High
$2.14
52-wk Low
$0.39

Summary

Name Age Since Current Position

Gary Jacob

70 2014 Chairman of the Board

James Sapirstein

54 2014 Chief Executive Officer, Director

John Cavan

58 2016 Chief Financial Officer

Robert Foster

58 2016 Chief Scientific Officer

Theresa Matkovits

49 2015 Senior Vice President—Drug Development

John Sullivan-Bolyai

67 2015 Chief Medical Officer

Tamar Howson

68 2016 Director

Thomas Adams

74 2016 Independent Director

Timothy Block

61 2013 Independent Director

John Brancaccio

69 2013 Independent Director

Arnold Lippa

69 2015 Independent Director

Biographies

Name Description

Gary Jacob

Dr. Gary S. Jacob, Ph.D. is Chairman of the Board of the Company. Dr. Jacob is currently the Chairman of the Board, President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he has held various positions since July 2008. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob currently serves as a director of Trovagene, Inc., a diagnostics company. Dr. Jacob has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.

James Sapirstein

Mr. James Sapirstein is Chief Executive Officer, Director of ContraVir Pharmaceuticals, Inc. Mr. Sapirstein was the chief executive officer of Alliqua Therapeutics at Alliqua Inc., where he helped lead the transformation of transdermal wound care and drug delivery technology into a premier wound care organization from October 2012 to February 2014. Mr. Sapirstein was the chief executive officer of Tobira Therapeutics, a New Jersey based biopharmaceutical company focused on the development of novel HIV and infectious disease compounds, from October 2006 to April 2011. From June 2002 until May 2005, Mr. Sapirstein was Executive Vice President for Serono Laboratories where he led a team of over 100 professionals to rebuild a struggling HIV and pediatric growth hormone business. Mr. Sapirstein also served in the Global Marketing group at Gilead, beginning in 2000 where he led and developed the global marketing strategy for its flagship HIV drug, Viread as well as played a key role in the development of the drug combination strategy that resulted in Gilead’s acquisition of Triangle’s nucleoside portfolio. He held a number of positions at Hoffmann-LaRoche, including Product Director and International Operations Manager, and was actively involved with numerous product launches including several antivirals. In 1996, he became the Director of International Marketing of the Infectious Disease Division at Bristol Myers Squibb (BMS). Mr. Sapirstein directed the international HIV product marketing strategy at BMS and was an integral part of the international development and launch of a number of infectious disease products while at BMS. Mr. Sapirstein is a director of Panther Biotechnology, Inc., a biotechnology company.

John Cavan

Mr. John T. Cavan is Chief Financial Officer of the company. He has more than 20 years of financial management experience in both public and private companies. Prior to joining ContraVir as interim CFO, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. Preceding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals, Inc. where he was instrumental in the company's initial public offering, through which Aegerion achieved a$2 billionmarket capitalization. He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals, Inc. and Alpharma. Mr. Cavan served in a variety of financial and operational positions early in his career during tenures with large multinational public companies, including Sony, American Express, International Specialty Products (an Ashland Company) and Nestlé U.S.A. Mr. Cavan currently serves on the Board of Directors of Vantage Health Systems. He holds a B.B.A in Accountancy fromIona Collegeand an M.B.A. in Finance fromSeton Hall University.

Robert Foster

Dr. Robert Foster, Ph.D., is Chief Scientific Officer of the Company. Dr. Foster has served as the Chief Executive Officer of Ciclofilin from January 2014 to the present, as Chief Executive Officer and Chief Scientific Officer of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia”) from August 2013 to February 2014, and as Chief Executive Officer of Isotechnika (TSX:ISA) from June 1993 through its merger with Aurinia in August 2013.

Theresa Matkovits

Ms. Theresa Matkovits is Senior Vice President—Drug Development of the Company. Theresa Matkovits, Ph.D., brings over 20+ years global drug development, commercialization, and leadership experience to ContraVir. Prior to joining ContraVir, from 2013 - 2015, Dr. Matkovits was with NPS Pharmaceuticals leading the integration of two commercial assets acquired from Takeda into NPS and leading the global development efforts for Natpara. From 2010 to 2013 Dr. Matkovits was Vice President, Innovation Leader for The Medicines Company leading the development efforts for ORBACTIVE. From 2007 to 2010 Dr. Matkovits spent 13 years with Novartis, taking on leadership roles in global development and U.S. medical affairs for the general medicine portfolio. Dr. Matkovits started her career at the Roche Institute of Molecular Biology and Organon where she held positions in clinical development in the Women's Health area. Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of NJ and completed her undergraduate studies at Alfred University.

John Sullivan-Bolyai

Dr. John Z. Sullivan-Bolyai M.D., is Chief Medical Officer of the Company. From August 2014 until January 2015, Dr. Sullivan- Bolyai was the Executive Director of Infectious Disease clinical research at Merck & Co. Inc. where he oversaw multiple HCV protocols in all three phases of clinical development. From June 2007 until August 2014, he was the Vice-President of Clinical Research at Idenix Pharmaceuticals Inc. where he managed all medical aspects of the HIV and HCV programs. Additionally, he was responsible for the transition of Idenix’s clinical team to Merck, which acquired Idenix. Prior to joining Idenix, Dr. Sullivan-Bolyai worked at Anadys Pharmaceuticals on hepatitis C and at Valeant Pharmaceuticals International on Valeant’s nucleotide prodrug for the treatment of chronic hepatitis B infection. Previously, he held various medical and operations positions at Biomeasure and Serono Laboratories in Massachusetts, working on coagulation, immunomodulatory, endocrine, and gastrointestinal compounds. He began his career with Hoffmann-La Roche where he worked on a variety of compounds for the treatment of bacterial infections, HCV and HIV. Dr. Sullivan-Bolyai received an MD, MPH from the University of Washington in Seattle. He completed his infectious diseases fellowship training at the Children’s Orthopedic Hospital and Medical Center, Seattle, WA, followed by academic positions at UCLA and the University of Illinois.

Tamar Howson

Ms. Tamar D. Howson serves as Director of the Company. Ms. Howson has an extensive track record earned across a distinguished career of more than 25 years in corporate and business development. Ms. Howson served previously as Senior Vice President of Corporate and Business Development at both SmithKline Beecham (now GSK) and Bristol-Myers Squibb as well as high-level positions at multiple other industry leaders. She has helped companies navigate external alliances, license negotiations, mergers and acquisitions, and venture capital investments. In 1999, she was awarded Healthcare Businesswomen’s Association’s “Woman of the Year” award. In addition to ContraVir, Ms. Howson currently serves on the Board of Directors for the International Partnership for Microbicides, Idenix Pharmaceuticals, Aradigm, and OXiGENE. Ms. Howson earned a B.Sc. in Chemical Engineering from Technion in Haifa, Israel, an M.S. in Chemical Engineering from City College of New York, and an MBA in Finance, International Business and Marketing from Columbia University.

Thomas Adams

Dr. Thomas H. Adams, Jr., Ph.D., is Independent Director of the Company. Dr. Adams is currently a director of Synergy Pharmaceuticals, Inc. In addition, Dr. Adams served as a director of IRIS International, Inc. since June 2005 and Chief Technology Officer of IRIS from April 2006 until November 2012 when it was acquired by Danaher Corporation. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. Previously, in 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams has significant public company experience serving as a director of Biosite Diagnostics, Inc. from 1989 to 1998 and as a director of Invitrogen from 2000 to 2002. He holds a Ph.D. in Biochemistry from the University of California, at Riverside.

Timothy Block

Dr. Timothy Block is Independent Director of the Company. Dr. Block is Professor of Microbiology and Immunology, Drexel University College of Medicine and Director of its Drexel Institute for Biotechnology and Virology Research, and is also the Co-founder and President of the Hepatitis B Foundation (HBF) and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research), the nation’s leading nonprofit organizations dedicated to finding a cure for hepatitis B and improving the lives of those affected worldwide through research, education and patient advocacy. Dr. Block is also President and CEO of the Pennsylvania Biotechnology Center. Dr. Block has been a member of medical school faculties as a professional researcher for more than 28 years, publishing more than 180 papers, 12 U.S. patents, and since 2006, has led or “co-led” more than $50 million in research funding. Honors include an honorary Medical Doctorate (Bulgarian Academy of Medicine); the Lifetime Achievement Award from the Centrals Bucks Chamber of Commerce; named one the regions 100 Most Outstanding People of the Century by the Daily Intelligencer; Distinguished Service Recognition from the National Cancer Institute’s Early Detection Research Network; and a Special Citation from the U.S. House of Representatives in recognition of “outstanding achievements.” Dr. Block has given frequent testimony to the U.S. Congress and State legislatures; has served on U.S. FDA and numerous NIH panels as well as commercial boards including the Bristol Myers Squibb Entecavir Advisory Board. In 2009, Dr. Block was named an elected Fellow of the American Association for the Advancement of Science (AAAS).

John Brancaccio

Mr. John P. Brancaccio CPA is Independent Director of the Company. Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Mr. Brancaccio is currently a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) as well as a director of Trovagene, Inc.

Arnold Lippa

Dr. Arnold S. Lippa, Ph.D., is Independent Director of the Company. Dr. Lippa has been Executive Chairman of the Board of Cortex Pharmaceuticals Inc., since March 2013, and was appointed Chief Scientific Officer in August 2015. Previously, he served as Chief Executive Officer and President. He is also Chairman of the Board of Xintria Pharmaceutical Corporation, which he co-founded in 2006. Dr. Lippa is a Managing Member and founder of T Morgen Capital, an investment and management company specializing in the creation and management of biomedical companies. He co-founded and currently is representing T Morgen Capital, Atypical BioCapital Management and Atypical BioVentures Fund, a life science fund management company and fund, respectively, both of which are affiliates of Aurora Capital. Dr. Lippa was a founder of DOV Pharmaceutical, Inc., and served as Chairman of the Board and Chief Executive Officer from its inception in April 1995 until 2005. Prior to DOV, Dr. Lippa co-founded and co-managed a number of life sciences companies, including Praxis Pharmaceuticals, Inc., which he co-founded and took public in 1985, serving as President and Chief Operating Officer from 1984 until 1987.

Basic Compensation